Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov:144:110012.
doi: 10.1016/j.mehy.2020.110012. Epub 2020 Jun 19.

Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis

Mohamed A Abouelkhair  1
Affiliations

Targeting adenosinergic pathway and adenosine A2A receptor signaling for the treatment of COVID-19: A hypothesis

Mohamed A Abouelkhair. Med Hypotheses. 2020 Nov.

Abstract

The most serious health issue today is the rapid outbreak of Coronavirus Disease 2019 (COVID-19). More than 6,973,427 confirmed cases were diagnosed in nearly 213 countries and territories around the world and two international conveyances, causing globally over 400,000 deaths. Epidemiology, risk factors, and clinical characteristics of COVID-19 patients have been identified, but the factors influencing the immune system against COVID-19 have not been well established. Upon infection or cell damage, high amounts of adenosine triphosphate (ATP) are released from damaged cells, which serve as mediators of inflammation through purinergic cell surface receptor signaling. As a protective mechanism to prevent excessive damage to host tissue, adenosine counteracts ATP's effects by adenosine receptor stimulation to suppress the pro-inflammatory response. Adenosine is seen as a major obstacle to the efficacy of immune therapies, and the adenosinergic axis components are critical therapeutic targets for cancer and microbial infections. Pharmacologic inhibitors or antibodies specific to adenosinergic pathway components or adenosine receptors in microbial and tumor therapy have shown efficacy in pre-clinical studies and are entering the clinical arena. In this review, we provide a novel hypothesis explaining the potential for improving the efficiency of innate and adaptive immune systems by targeting adenosinergic pathway components and adenosine A2A receptor signaling for the treatment of COVID-19.

Keywords: Adenosine; CD39; CD73; COVID-19; Immunotherapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Targeting the adenosinergic pathway components by using anti-CD73, anti-CD39 monoclonal antibodies and A2AR receptor antagonist.
See this image and copyright information in PMC

References

    1. Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2). - PMC - PubMed
    1. Worldometer. Covid-19 coronavirus pandemic; 2020, May 02.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. - PMC - PubMed
    1. Taghizadeh-Hesary F., Akbari H. The powerful immune system against powerful COVID-19: a hypothesis. Med Hypotheses. 2020;109762 - PMC - PubMed
    1. Kindler E., Thiel V. SARS-CoV and IFN: too little, too late. Cell Host Microb. 2016;19(2):139–141. - PMC - PubMed

MeSH terms